Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).”In the company’s words, NCT06534437 on ClinicalTrials.gov
- Tested for
- Non-Hodgkin Lymphoma, B-cell
- Main trialPhase 2
- “The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to groups at the same time: * Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma * Group 2 - patients who have exhausted all standard treatment options including at least 2 prior lines of…”In the company’s words, NCT06534437 on ClinicalTrials.gov
- Other names
- SEL24 · Dapolsertib hydrochloride
Other drugs for Non-Hodgkin Lymphoma, B-cell
- GlofitamabRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- TocilizumabRoche · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- XNW5004Evopoint Biosciences Inc. · Phase 3
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2026 | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026